Clinical Trial Update: A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating tolerability of different doses of Obrixtamig (BI 764532) in combination with Ezabenlimab in patients with small cell lung cancer and o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors
• Small Cell Lung Cancer

Drugs mentioned

• Obrixtamig (BI 764532)
• ezabenlimab (ezabenlimab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Small Cell Lung Carcinoma (SCLC), Neuroendocrine Neoplasms | Phase 1 | Status: ACTIVE_NOT_RECRUITING